<DOC>
	<DOCNO>NCT02296905</DOCNO>
	<brief_summary>This open-label , single-dose study design ass pharmacokinetics safety ABT-493 and/or ABT-530 subject impair hepatic function compare subject normal hepatic function . Twenty-four subject select enrol accord subject selection criterion : 6 subject mild stable chronic hepatic impairment ( Group I ) , 6 subject moderate stable chronic hepatic impairment ( Group II ) , 6 subject severe stable chronic hepatic impairment ( Group III ) 6 subject normal hepatic function ( Group IV ) .</brief_summary>
	<brief_title>Pharmacokinetics Safety ABT-493 and/or ABT-530 Subjects With Normal Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>All Subjects If female , subject must either postmenopausal least 2 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) . Females must negative result pregnancy test perform : At Screening urine specimen obtain within 28 day prior initial study drug administration , On serum sample obtain Study Day 1 Period 1 . Males must surgically sterile practice least one follow method birth control ( sperm donation within study period allow ) : Abstinence Partner ( ) use Intrauterine Device ( IUD ) Partner ( ) use oral , injected , implanted method hormonal contraceptive Subject and/or partner ( ) use doublebarrier method . Subjects Normal Hepatic Function In addition inclusion criterion subject , follow criterion must meet subject normal hepatic function enrol Group IV : Judged general good health base upon result medical history , physical examination , laboratory profile ( include liver function parameter within limit normal ) 12lead electrocardiogram ( ECG ) . Negative hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCV Ab ) test result . Body Mass Index ( BMI ) ≥ 18 &lt; 38 kg/m2 , inclusive . Subjects Hepatic Impairment In addition inclusion criterion subject , follow criterion must meet subject hepatic impairment enrol Groups I , II III : Judged stable condition acceptable study participation base upon result medical history , physical examination , laboratory profile ECG . BMI ≥ 18 &lt; 38 kg/m2 , inclusive , subject hepatic impairment without ascites subject subclinical ascites detect ultrasound imaging . For subject hepatic impairment clinically significant ascites , BMI permit range ≥ 18 &lt; 40 kg/m2 , inclusive . ChildPugh classification Categories A ( mild ) , B ( moderate ) , C ( severe ) . Medical history chronic liver disease include limited chronic hepatitis B , history alcoholic liver disease chronic hepatitis C. Presence clinically significant hepatic impairment indicate either : 1 . Evidence liver cirrhosis OR 2 . Medical history least one follow criterion : Clinical diagnosis liver disease Total bilirubin , &gt; 2 mg/dl , indirect/direct ratio &lt; 1 prolong prothrombin time elevation &gt; 1.7 albumin value lower limit laboratory reference range exclude nonhepatic cause previous laboratory abnormality . History significant sensitivity drug . Pregnant breastfeed female . Recent ( 6month ) history drug alcohol abuse . Positive test result hepatitis A virus immunoglobulin M ( HAVIgM ) human immunodeficiency virus antibody ( HIV Ab ) . Negative HIV status confirm Screening result maintain confidentially study site . Detectable HCV RNA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Hepatitis C Virus Infection</keyword>
</DOC>